Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

[Severe pneumococcal infections in the elderly - preventable by vaccination].

Hof H, Fahr A, Holfelder M, Schwarz R, Oberdorfer K.

Z Gerontol Geriatr. 2013 Feb;46(2):160-6. doi: 10.1007/s00391-012-0339-x. German.

PMID:
23250308
2.

[Pneumococcal sepsis in aged patients - implications for the vaccination of seniors against pneumococci].

Hof H, Oberdorfer K, Singer S, Holfelder M, Fahr A.

Dtsch Med Wochenschr. 2011 Dec;136(49):2562-4. doi: 10.1055/s-0031-1292842. Epub 2011 Nov 30. German.

PMID:
22131079
3.

Laboratory surveillance of invasive pneumococcal disease in Australia in 2001 to 2002--implications for vaccine serotype coverage.

Watson M, Bayley K, Bell JM, Gilbert GL, Hogg G, Keil AD, Krause V, Murphy D, Roche P, Smith HV, Stewart MG, Stylianopoulos J, Turnidge J.

Commun Dis Intell Q Rep. 2003;27(4):478-87.

4.

[Invasive pneumococcal disease in Germany in the era of pneumococcal conjugate vaccination].

Imöhl M, van der Linden M.

Dtsch Med Wochenschr. 2014 Jun;139(25-26):1346-51. doi: 10.1055/s-0034-1370126. Epub 2014 Jun 10. German.

PMID:
24914512
5.

Regional differences in serotype distribution, pneumococcal vaccine coverage, and antimicrobial resistance of invasive pneumococcal disease among German federal states.

Imöhl M, Reinert RR, van der Linden M.

Int J Med Microbiol. 2010 Apr;300(4):237-47. doi: 10.1016/j.ijmm.2009.05.005. Epub 2009 Jul 14.

PMID:
19604721
6.
7.

Laboratory surveillance of invasive pneumococcal disease in Australia, 2003 predicting the future impact of the universal childhood conjugate vaccine program.

Watson M, Roche P, Bayley K, Bell JM, Collignon P, Gilbert GL, Hogg G, Keil AD, Krause V, Murphy D, Smith HV, Brown M, Stylianopoulos J, Turnidge J.

Commun Dis Intell Q Rep. 2004;28(4):455-64.

8.

Impact of conjugate pneumococcal vaccines on the changing epidemiology of pneumococcal infections.

Zangeneh TT, Baracco G, Al-Tawfiq JA.

Expert Rev Vaccines. 2011 Mar;10(3):345-53. doi: 10.1586/erv.11.1. Review.

PMID:
21434802
9.

Pneumococcal vaccination of elderly adults: new paradigms for protection.

Jackson LA, Janoff EN.

Clin Infect Dis. 2008 Nov 15;47(10):1328-38. doi: 10.1086/592691. Review.

PMID:
18844484
10.

Cost-effectiveness of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK.

Jiang Y, Gauthier A, Keeping S, Carroll S.

Expert Rev Pharmacoecon Outcomes Res. 2014 Dec;14(6):913-27. doi: 10.1586/14737167.2014.950232. Epub 2014 Sep 5.

PMID:
25189087
11.

Declining invasive pneumococcal disease in the U.S. elderly.

McBean AM, Park YT, Caldwell D, Yu X.

Vaccine. 2005 Dec 1;23(48-49):5641-5. Epub 2005 Jul 27.

PMID:
16111788
12.

Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults.

Durando P, Faust SN, Fletcher M, Krizova P, Torres A, Welte T.

Clin Microbiol Infect. 2013 Oct;19 Suppl 1:1-9. doi: 10.1111/1469-0691.12320. Review.

13.

Pneumococcal vaccination rates in adults in Germany: an analysis of statutory health insurance data on more than 850,000 individuals.

Theidel U, Kuhlmann A, Braem A.

Dtsch Arztebl Int. 2013 Nov 1;110(44):743-50. doi: 10.3238/arztebl.2013.0743.

14.

Pneumococcal Conjugated Vaccine Reduces the High Mortality for Community-Acquired Pneumonia in the Elderly: an Italian Regional Experience.

Baldo V, Cocchio S, Gallo T, Furlan P, Romor P, Bertoncello C, Buja A, Baldovin T.

PLoS One. 2016 Nov 15;11(11):e0166637. doi: 10.1371/journal.pone.0166637. eCollection 2016.

15.

Pneumococcal infection and vaccination in the elderly.

Vlasich C.

Vaccine. 2001 Mar 21;19(17-19):2233-7.

PMID:
11257339
16.

Additive preventive effect of influenza and pneumococcal vaccines in the elderly: results of a large cohort study.

Mahamat A, Daurès JP, de Wzieres B.

Hum Vaccin Immunother. 2013 Jan;9(1):128-35. doi: 10.4161/hv.22550.

17.

The risk of pneumococcal infections after immunization with pneumococcal conjugate vaccine compared to non-vaccinated inflammatory arthritis patients.

Nagel J, Geborek P, Saxne T, Jönsson G, Englund M, Petersson IF, Nilsson JÅ, Kapetanovic MC.

Scand J Rheumatol. 2015;44(4):271-9. doi: 10.3109/03009742.2014.984754. Epub 2015 Feb 6.

PMID:
25656734
18.

A public health and budget impact analysis of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK.

Jiang Y, Gauthier A, Keeping S, Carroll S.

Expert Rev Pharmacoecon Outcomes Res. 2014 Dec;14(6):901-11. doi: 10.1586/14737167.2014.953932. Epub 2014 Sep 4.

PMID:
25186657
19.

Antibiotic susceptibility rates of invasive pneumococci before and after the introduction of pneumococcal conjugate vaccination in Germany.

Imöhl M, Reinert RR, van der Linden M.

Int J Med Microbiol. 2015 Oct;305(7):776-83. doi: 10.1016/j.ijmm.2015.08.031. Epub 2015 Aug 22.

PMID:
26324014
20.

Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis.

Rozenbaum MH, van Hoek AJ, Fleming D, Trotter CL, Miller E, Edmunds WJ.

BMJ. 2012 Oct 26;345:e6879. doi: 10.1136/bmj.e6879.

Supplemental Content

Support Center